TA, B., MW, M., LB, L., JM, O., DM, M., RE, F., . . . RA, S. (2021). Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia. Dove Medical Press.
Style de citation Chicago (17e éd.)TA, Berger, Manry MW, Lindsell LB, Osher JM, Miller DM, Foster RE, Riemann CD, Petersen MR, et Sisk RA. Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia. Dove Medical Press, 2021.
Style de citation MLA (8e éd.)TA, Berger, et al. Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia. Dove Medical Press, 2021.
Attention : ces citations peuvent ne pas être correctes à 100%.